Published in Healthcare Finance, Tax and Law Weekly, August 15th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Danish Medicines Agency.
Report 1: An article published in the New England Journal of Medicine (NEJM) has raised concern about a small increased risk of myocardial infarction and cardiovascular death in patients with type 2 diabetes treated with rosiglitazone. The article, based on an analysis of data retrieved from 42 clinical studies, showed a small increased risk for myocardial infarction and cardiovascular death among approximately 15,500 patients treated with rosiglitazone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly